Stanford inventors develop a machine learning algorithm that accurately classifies patients suffering from an aggressive cancer, pancreatic ductal adenocarcinoma (PDAC), into prognostic groups that can predict differences in patient survival times.
Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.